SCHEMBL1198317

SCHEMBL1198317

CNC(=O)COc1cc(Nc2ncc(F)c(Nc3ccc4c(c3)NC(=O)C(C)(C)O4)n2)ccc1OC

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 19/20 0.77
JAK2 O60674 2/20 0.66
EGFR P00533 2/20 0.66
LCK P06239 2/20 0.66
LYN P07948 2/20 0.66
FGFR4 P22455 2/20 0.66
ADORA3 P0DMS8 2/20 0.55
TYRO3 Q06418 2/20 0.55
BMPR1B O00238 1/20 0.55
CDC7 O00311 1/20 0.55
PIK3CD O00329 1/20 0.55
PLK4 O00444 1/20 0.55
STK25 O00506 1/20 0.55
CIT O14578 1/20 0.55
RIOK3 O14730 1/20 0.55
CHEK1 O14757 1/20 0.55
IKBKB O14920 1/20 0.55
AURKA O14965 1/20 0.55
GAK O14976 1/20 0.55
CHUK O15111 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1198156 0.92 SYK (0.77) SYKJAK2EGFRLCKLYN
SCHEMBL3837515 0.87 SYK (1.00) SYKJAK2EGFRLCKLYN
SCHEMBL14837327 0.85 SYK (0.74) SYKJAK2EGFRLCKLYN
SCHEMBL2102713 0.84 SYK (0.66) SYKJAK2EGFRLCKLYN
SCHEMBL1380946 0.83 SYK (0.67) SYKJAK2EGFRLCKLYN
SCHEMBL29794592 0.82 SYK (1.00) SYKJAK2EGFRLCKLYN
SCHEMBL4002240 0.82 SYK (0.61) SYKJAK2EGFRLCKLYN
SCHEMBL14607333 0.81 SYK (0.70) SYKJAK2EGFRLCKLYN
SCHEMBL2103278 0.81 SYK (0.69) SYKJAK2EGFRLCKLYN
SCHEMBL12100695 0.81 SYK (0.74) SYKJAK2EGFRLCKLYN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080260754-A1 COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY RIGEL PHARMACEUTICALS, INC. 2008-10-23 US claimed
US-8299087-B2 Compositions and methods for inhibition of the JAK pathway RIGEL PHARMACEUTICALS, INC. (US) 2012-10-30 US disclosed
US-20110027856-A1 COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY RIGEL PHARMACEUTICALS, INC. (US) 2011-02-03 US disclosed
US-7834024-B2 Compositions and methods for inhibition of the JAK pathway RIGEL PHARMACEUTICALS, INC. (US) 2010-11-16 US disclosed
US-20080260754-A1 COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY RIGEL PHARMACEUTICALS, INC. 2008-10-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080260754-A1 COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY JAK3, JAK2, JAK1 SYK 62/4885JAK2 2/4885EGFR 529/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.